Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
RNAi screen for vorinostat resistance genes - Primary Screen
Assay data:450 Active, 18118 Tested
SummaryPubMed Citation
siRNA Circadian Assay
Assay data:527 Active, 33364 Tested
SummaryPubMed CitationRelated BioAssays by Depositor
Late stage assay provider results from the probe development effort to identify inhibitors of PME-1: Fluorescence-based biochemical gel-based ABPP inhibition and selectivity
Assay data:24 Tested
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
An siRNA screen for human genes that are involved in human papilloma virus (HPV) E2 transcriptional repression of the E6 and E7 oncogenes
Assay data:497 Active, 21019 Tested
Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Dharmacon Library)
Assay data:826 Active, 18119 Tested
Genome-wide high-content siRNA screens for regulators of Parkin translocation in selective mitophagy (Ambion Library)
Assay data:9227 Active, 64752 Tested
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA1: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situ
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late stage assay provider results from the probe development effort to identify selective inhibitors of LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis in situ
Late stage assay provider results from the extended probe development effort to identify inhibitors of LYPLA1 and LYPLA2: LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
A whole genome RNAi screen highlights components of the ER/Golgi as a prominent source of resistance to immunotoxin-mediated cytotoxicity
Assay data:555 Active, 64752 Tested
InfectX: Pathogen infection siRNA screens
Assay data:115372 Tested
Identification of proteins required for the processing of the EWS-FLI1 nascent transcript
Assay data:59220 Tested
A screen to identify genes that regulate lymphatic endothelial cell migration - Primary Screen
Assay data:1034 Active, 18120 Tested
SummaryRelated BioAssays by Depositor
A screen to identify synthetic lethal interactions with E-cadherin in an MCF10A isogenic cell line
Assay data:2442 Active, 18052 Tested
Genome-wide siRNA screen of genes regulating the Lipopolysaccharide-induced TNF-alpha response in human macrophages_Primary screen TNF readout
Assay data:2853 Active, 18113 Tested
SummaryRelated BioAssays by Same Project
Genome-wide siRNA screen of genes regulating the Lipopolysaccharide-induced TNF-alpha response in human macrophages_Secondary screen TNF readout
Assay data:731 Active, 3462 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on